for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Mitsubishi Tanabe Pharma Corp

4508.T

Latest Trade

1,244.00JPY

Change

40.00(+3.32%)

Volume

2,172,900

Today's Range

1,214.00

 - 

1,249.00

52 Week Range

1,128.00

 - 

1,796.00

As of on the Tokyo Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
1,204.00
Open
1,228.00
Volume
2,172,900
3M AVG Volume
22.95
Today's High
1,249.00
Today's Low
1,214.00
52 Week High
1,796.00
52 Week Low
1,128.00
Shares Out (MIL)
560.78
Market Cap (MIL)
698,403.90
Forward P/E
47.10
Dividend (Yield %)
4.50

Next Event

Q2 2020 Mitsubishi Tanabe Pharma Corp Earnings Release

Latest Developments

More

Viela Bio Enters Strategic Collaboration With Mitsubishi Tanabe Pharma

EU Medicines Agency Says Application For Initial Marketing Authorization For Mitsubishi Tanabe Pharma's Radicava (Edaravone) Has Been Withdrawn

Tanabe Research Says U.S. FDA Accepted Its IND Application For TR1801-ADC

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Mitsubishi Tanabe Pharma Corp

Mitsubishi Tanabe Pharma Corporation is a Japan-based company mainly engaged in the manufacture and sale of pharmaceutical products. The medical supplies business is engaged in the research, development, manufacture and sale of ethical pharmaceutical and non-prescription drugs. The Company’s subsidiaries receive raw materials from the company and sell products locally.

Industry

Major Drugs

Contact Info

3-2-10, Dosho-machi, Chuo-ku

+81.6.62055085

https://www.mt-pharma.co.jp/

Executive Leadership

Masayuki Mitsuka

Executive President, President, Representative Director

Megumi Ohtaki

Chief Compliance Officer, Executive Officer, Director of Pharmaceutical Affairs

Takashi Kobayashi

Senior Managing Executive Officer, Representative Director

Yoshiaki Ishizaki

Managing Executive Officer, Director

Seiichi Murakami

Managing Executive Officer, Director

Key Stats

3.11 mean rating - 9 analysts
Sell
Hold
Buy
Revenue (MM, JPY)

2017

0.4K

2018

0.4K

2019

0.4K

2020(E)

0.4K
EPS (JPY)

2017

127.030

2018

103.350

2019

66.640

2020(E)

11.613
Price To Earnings (TTM)
23.03
Price To Sales (TTM)
1.67
Price To Book (MRQ)
0.79
Price To Cash Flow (TTM)
18.80
Total Debt To Equity (MRQ)
0.02
LT Debt To Equity (MRQ)
0.02
Return on Investment (TTM)
2.61
Return on Equity (TTM)
2.38

Latest News

Latest News

BRIEF-Mitsubishi Tanabe Pharma Says Novartis Pharma Has Filed Request For Arbitration Against It

* SAYS NOVARTIS PHARMA HAS FILED REQUEST FOR ARBITRATION AGAINST IT

BRIEF-Dyadic International Announces R&D Collaboration With Mitsubishi Tanabe Pharma Corp

* ANNOUNCES RESEARCH AND DEVELOPMENT COLLABORATION WITH MITSUBISHI TANABE PHARMA CORPORATION TO PRODUCE TWO TARGET PROTEINS IN C1

BRIEF-Mitsubishi Tanabe Pharma updates license agreement with Kolon Life Secience on Invossa

* Says it notified Kolon Life Secience, Inc. (KLS) that the co seeks to cancel the license agreement between the co and KLS for Invossa, a cell therapy product for improvement of knee osteoarthritis symptoms

BRIEF-Mitsubishi Tanabe Pharma completes purchase of NeuroDerm

Mitsubishi Tanabe Pharma Corp * Says it completed purchase of NeuroDerm Ltd * Purchase plan was announced on July 24 Source text in Japanese:https://goo.gl/LcG5Lm Further company coverage: (Beijing Headline News)

BRIEF- Mitsubishi Tanabe Pharma sells drug sales unit

* Says it sold 100 percent stake in a drug sales unit to Nipro, on Oct. 1

BRIEF-Neuroderm calls shareholders meeting to approve Mitsubishi Tanabe acquisition

* Neuroderm announces extraordinary general meeting of shareholders to approve acquisition by Mitsubishi Tanabe Pharma Corporation Source text for Eikon: Further company coverage:

Mitsubishi Tanabe Pharma to buy Israel's Neuroderm for $1.1 billion

Japan's Mitsubishi Tanabe Pharma Corp <4508.T> has agreed to buy Israeli drug maker Neuroderm <NDRM.O> for $1.1 billion in cash as part of a strategy to grow its business in the United States.

Japan's Mitsubishi Tanabe Pharma to buy Israel's Neuroderm for $1.1 bln

Japan's Mitsubishi Tanabe Pharma Corp said on Monday it will acquire Israeli drug maker Neuroderm for $1.1 billion in an all-cash deal to expand its overseas business.

BRIEF- Mitsubishi Chemical Holdings consolidated subsidiary to buy NeuroDerm for about $1.1 bln

* Says its consolidated subsidiary Mitsubishi Tanabe Pharma Corp will buy NeuroDerm Ltd, for about $1.1 billion (about 124.1 billion yen), $39 per share, effective October

BRIEF-Neuroderm enters definitive agreement to be acquired by Mitsubishi Tanabe Pharma for $1.1 bln

* Neuroderm enters definitive agreement to be acquired by Mitsubishi Tanabe Pharma corporation for US$1.1 billion in cash

BRIEF-R&I affirms Mitsubishi Tanabe Pharma's rating at "A+" and announces stable outlook-R&I

* Says Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "A+" -R&I

FDA approves first ALS treatment in more than two decades

The Food and Drug Administration on Friday approved Mitsubishi Tanabe Pharma Corp's treatment for fatal neurological disorder amyotrophic lateral sclerosis (ALS), marking the first such U.S. regulatory approval in more than two decades.

BRIEF-Mitsubishi Tanabe Pharma to sell drug sales unit to Nipro after company division

* Says the co will transfer generic drug business and part of long-listed drugs business to its wholly owned unit, an Osaka-based drug sales firm, via company division

BRIEF-Mitsubishi Tanabe Pharma to set up vaccine JV in Kagawa

* Says it plans to set up JV in Kagawa with The Research Foundation for Microbial Diseases of Osaka University

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up